Biogen Idec Oral MS Agent BG-12 Safety Takes Center Stage At Firm’s R&D Day
This article was originally published in Pharmaceutical Approvals Monthly
Biogen Idec highlighted the safety profile of its oral multiple sclerosis compound BG-12 during its recent R&D Day.
You may also be interested in...
Tysabri’s REMS could prove to be a model for drugs with serious safety signals.
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.